A Phase 1b/2 Open-Label, Multicenter Study of RMC-6236 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS‑Mutated Non-Small Cell Lung Cancer (NSCLC) – subprotocol B.
Principal Investigator
Dr. G. Ruiter
Drugs
RMC 6236 (panRASon inhibitor) + Pembrolizumab (+chemotherapy)
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with each other.
The first two subprotocols include the following:
Read more on clinicaltrials.gov